EFTA Document EFTA01453440
might saddle state Medicaid programs with steep costs. US is the only major health-care market remaining without any meaningful drug price controls -- increased risk for the sector once the Congress gets involved, especially if focused primarily on pricing. Description Trade Date Quantity Last Prices Unit Cost Market Value Unrealized G/L SANGAIIO BIOSCIENCES 05/28/2013 50,000.00 5 19.80 $ 8.44 $ 990,000.00 $ 567,786.00 BIOGEN 02/14/2012 2,095.30 $ 312.60 $ 119.55 $ 654,
Summary
might saddle state Medicaid programs with steep costs. US is the only major health-care market remaining without any meaningful drug price controls -- increased risk for the sector once the Congress gets involved, especially if focused primarily on pricing. Description Trade Date Quantity Last Prices Unit Cost Market Value Unrealized G/L SANGAIIO BIOSCIENCES 05/28/2013 50,000.00 5 19.80 $ 8.44 $ 990,000.00 $ 567,786.00 BIOGEN 02/14/2012 2,095.30 $ 312.60 $ 119.55 $ 654,
Ask AI About This Document
Extracted Text (OCR)
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
2512014Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.